Lunwell technology platform
The silver-coated textile platform: from surface to ionic interface
Lunwell technology combines an open polyester mesh of 18–20 threads/cm², a homogeneous elemental-silver surface and controlled Ag⁺ availability in one wound-contact layer.
Lunwell’s technological distinction is not simply that it contains silver. The homogeneous coating of silver on the polyester fibres, the contact created by the open mesh and the availability of Ag⁺ ions across the use period are engineered as one system.
- Carrier
- Porous polyester mesh
- Mesh density
- 18–20 threads/cm²
- Active surface
- ≥99% pure elemental silver
- Distribution
- SEM homogeneity criterion
- Release criterion
- <10 ppm
- Active species
- Ag⁺ ion
Published / updated: 11.08.2026
Silver wound dressings are not all the same. Total silver content alone does not explain product behaviour. Carrier structure, surface distribution, contact area and the way silver ions become available in a fluid environment together define the antimicrobial interface.
1. Textile carrier: an open, flexible mesh
Lunwell uses a single-layer, flexible, porous polyester mesh. Its technical acceptance criterion specifies a weave density of 18–20 threads per square centimetre. This open geometry allows the material to conform to the wound surface and permits exudate to pass towards the secondary dressing.
The carrier is not absorbent. Its role is not to retain fluid inside the material, but to create a non-adherent antimicrobial interface between the wound bed and the outer dressing. Exudate management and antimicrobial contact are therefore performed by separate but coordinated layers.
2. Elemental silver: an active surface, not a filler
Lunwell uses elemental metallic silver with a purity of at least 99%. The polyester mesh carries the silver as a homogeneous surface coating. Product specifications require a consistent bright silver-grey appearance and homogeneous distribution by SEM analysis. This design turns silver from a randomly dispersed additive into the functional surface that contacts the wound.
3. The ionic interface: why Ag⁺ is central
When the metallic surface contacts moisture, oxygen and ions in wound fluid, a fraction becomes bioavailable as Ag⁺. This is the antimicrobial species that interacts directly with bacteria. Ag⁺ can act simultaneously on the cell envelope, membrane energy balance, sulfur-containing protein groups and proteins involved in cell-wall synthesis.
- Silver is present as a homogeneous surface coating.
- The moist contact environment makes Ag⁺ bioavailable.
- Ag⁺ engages multiple cellular targets.
- Controlled availability matters as much as total silver content.
4. What does nanotechnology mean here?
In Lunwell, nanotechnology describes the engineering of the silver surface architecture and active area. The bioavailable antimicrobial species is ionic silver. In the 2026 chemical characterisation, the device was extracted for seven days at 37 ± 1 °C; ionic silver was measured, while no nanoscale silver-particle release was detected under the applied test conditions.
5. Design quality criteria
- A homogeneous metallic-silver appearance across the surface
- Homogeneous silver distribution by SEM analysis
- A mesh density of 18–20 threads/cm²
- Silver purity of at least 99%
- A product acceptance criterion of <10 ppm for silver release
- A sterile, single-use wound-contact layer
Taken together, these criteria make Lunwell more than a textile that contains silver. It is a wound-contact platform in which geometry, surface coating and ionic availability are controlled as one architecture.
6. The platform’s role in the clinical system
The open-mesh contact layer conforms to different wound geometries while preserving the exudate-management role of the secondary dressing. This separation of functions allows a wound-care professional to select absorbency and fixation according to the wound while positioning the antimicrobial surface directly at the wound bed.
References
- Argen Medikal ve Sağlık Ürünleri A.Ş.. Silver Wound Dressing Design Dossier, DD01, Revision 12 (2025).
- CanceRNA Biotechnology. Toxicological Risk Assessment Result Report — TRA_26_3_1_Argen_Lunwell_2412003 (2026).